Loading...
Market
What will be AbbVie's market position in Alzheimer's treatment pipeline by end of 2025?
2
Resolution / Starting Odds
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
Market analysis reports or industry publications
Story
AbbVie Acquires Privately Held Aliada Therapeutics for $1.4 Billion, Boosting Alzheimer's Focus with ALIA-1758
Oct 28, 2024, 12:11 PM
AbbVie Inc. has announced the acquisition of privately held Aliada Therapeutics for $1.4 billion in cash. This strategic move aims to bolster AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. The acquisition includes Aliada's lead compound, ALIA-1758, and novel blood-brain barrier technology. The deal represents a significant return on investment for venture capital, with an initial investment of $33 million yielding $1.4 billion.
View original story
Similar markets
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Yes • 50%
No • 50%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Biogen • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Donanemab leads • 25%
Leqembi leads • 25%
Both have equal share • 25%
Other treatments lead • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
No dominant company • 25%